Japan Tissue EngineeringJapan Tissue Engineering Co., Ltd.7774東証グロース精密機器FY ending Mar 2026, non-consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Regenerative Medicine Business | +0.4%5y | 1,4799.8% | 1,4062.8% | 1,40719.4% | 1,49314.6% | 1,3545.8% |
| Custom Development and Manufacturing Business | -5.4%5y | 39148.3% | 41937.6% | 86670.6% | 71457.7% | 54659.9% |
| Research and Development Support Business | — | 23310.9% | 207-1.2% | 24238.8% | 24827.2% | — |
| LabCyte Business | N/A | — | — | — | 24827.2% | 28218.7% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第28期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第27期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第26期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第25期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第24期(2021/04/01－2022/03/31)
EDINET (FSA Japan)
有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 41 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.